(Q46952551)

English

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells

scientific article published on 13 October 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

1 reference

based on heuristic

inferred from title

author name string

Chie Hirayama

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Hiroshi Watanabe

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Reiko Nakashima

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Takeru Nanbu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Akinobu Hamada

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Akihiko Kuniyasu

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Hitoshi Nakayama

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Tatsuya Kawaguchi

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Hideyuki Saito

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

publication date

13 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Pharmaceutical Research

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

25

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

827-835

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

hOCT 1 and resistance to imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional consequence of MDR1 expression on imatinib intracellular concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11095-007-9376-3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17934801

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46952551&oldid=2139482263"